Durable clinical and immunologic response to an off-the-shelf EWSR1-FLI1 peptide vaccine in metastatic Ewing sarcoma.
A personalized cancer vaccine kept a patient with advanced Ewing sarcoma stable for over two years by training immune cells to recognize tumor markers.
Off-the-shelf multi-peptide vaccine spanning the EWSR1-FLI1 fusion breakpoint induced de novo polyfunctional CD4+ T-cell responses (detectable by month 7, persisting >2 years) and maintained disease stability for >26 months in a patient with high-burden metastatic Ewing sarcoma. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- First-in-human case with longitudinal immune monitoring
- Category
- precision_oncology
- Maturity
- Validated
Why it surfaced
First-in-human data for fusion-derived peptide vaccine in Ewing sarcoma, a rare pediatric/young-adult cancer with no established immunotherapy. Published in NPJ Precision Oncology; directly supports the concept of off-the-shelf fusion-targeting vaccines for recurrent gene-fusion cancers. Conservative cap applied due to n=1 design.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.